amelimumab (SY101) / Tasly - LARVOL DELTA

SY101 - Pertussis resurgence: understanding epidemiological trends, immune and vaccine challenges, and policy responses (ESCMID Global 2026) - "The third talk will delve into genomic surveillance, addressing how the evolution of Bordetella pertussis is influencing transmission and vaccine effectiveness. The final presentation will explore the immunological challenges that have limited the long-term success of acellular vaccines and discuss promising innovations in vaccine design, maternal immunisation, and booster strategies aimed at restoring durable protection."

Clinical • Infectious Disease • Pertussis • Respiratory Diseases

SY101. Automated Anesthesia Delivery, the US Experience (non-CME) (ASA 2024) - "DESCRIPTION Join three leading anesthesiologists as they present real-world outcomes of automated inhalational anesthesia delivery using End-tidal Control, demonstrating how it impacts patient care, drives efficiency, and reduces anesthetic agent usage. GE Healthcare, Corporate Supporter"

Anesthesia

SY101. Checkpoints on Anti-Osteoporosis Medications: Clinical and Biological Considerations (ENDO 2023) - "DESCRIPTION The rationale for and approach to drug holidays in the setting of bisphosphonate therapy may not translate well to other anti-osteoporosis medications, as simple discontinuation of some such drugs may worsen fracture risk. Therefore, appropriate sequences and suitable timing for stopping anti-osteoporosis medication are of greatest interest to both doctors and patients."

Clinical • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

A phase Ia dose-escalation trial of Ametumumab (a fully human monoclonal antibody against epidermal growth factor receptor) in patients with advanced solid malignancies. (PubMed, Ther Adv Med Oncol) - "The Ametumumab was well tolerated and safe in patients with advanced solid malignancies, exhibiting minimal immunogenicity, a long half-life, high levels of drug exposure in the blood, and preliminary effectiveness. The trial was registered with CTR20170343 on 10 April 2017, The China Center for Drug Evaluation."

Journal • Metastases • P1 data • Oncology • Pain • Renal Disease • Solid Tumor • EGFR

A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer (clinicaltrials.gov) - P2b | N=84 | Not yet recruiting | Sponsor: Shanghai Celfuture Biotech Co., Ltd.

Combination therapy • Metastases • New P2b trial • Colon Cancer • Colorectal Adenocarcinoma • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • KRAS • NRAS • RAS